BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 25930118)

  • 1. Fabrication of cell culture-derived influenza vaccine dissolvable microstructures and evaluation of immunogenicity in guinea pigs.
    Bonificio A; Ghartey-Tagoe E; Gallorini S; Baudner B; Chen G; Singh P; O'Hagan DT; Kommareddy S
    Vaccine; 2015 Jun; 33(25):2930-8. PubMed ID: 25930118
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influenza subunit vaccine coated microneedle patches elicit comparable immune responses to intramuscular injection in guinea pigs.
    Kommareddy S; Baudner BC; Bonificio A; Gallorini S; Palladino G; Determan AS; Dohmeier DM; Kroells KD; Sternjohn JR; Singh M; Dormitzer PR; Hansen KJ; O'Hagan DT
    Vaccine; 2013 Jul; 31(34):3435-41. PubMed ID: 23398932
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improved immunogenicity of individual influenza vaccine components delivered with a novel dissolving microneedle patch stable at room temperature.
    Vassilieva EV; Kalluri H; McAllister D; Taherbhai MT; Esser ES; Pewin WP; Pulit-Penaloza JA; Prausnitz MR; Compans RW; Skountzou I
    Drug Deliv Transl Res; 2015 Aug; 5(4):360-71. PubMed ID: 25895053
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dissolvable microneedle patches for the delivery of cell-culture-derived influenza vaccine antigens.
    Kommareddy S; Baudner BC; Oh S; Kwon SY; Singh M; O'Hagan DT
    J Pharm Sci; 2012 Mar; 101(3):1021-7. PubMed ID: 22190403
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influenza vaccine immunogenicity in 6- to 23-month-old children: are identical antigens necessary for priming?
    Walter EB; Neuzil KM; Zhu Y; Fairchok MP; Gagliano ME; Monto AS; Englund JA
    Pediatrics; 2006 Sep; 118(3):e570-8. PubMed ID: 16950948
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neutralizing antibody but not hemagglutination antibody provides accurate evaluation for protective immune response to H5N1 avian influenza virus in vaccinated rabbits.
    Zhu H; Ding X; Chen X; Yao P; Xu F; Xie R; Yang Z; Liang W; Zhang Y; Li Y; Shen J; He P; Guo Z; Su B; Sun S; Zhu Z
    Vaccine; 2011 Jul; 29(33):5421-3. PubMed ID: 21645575
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preparation of highly concentrated influenza vaccine for use in novel delivery approaches.
    Kommareddy S; Bonificio A; Gallorini S; Baudner B; Singh M; O'Hagan D
    J Pharm Sci; 2013 Mar; 102(3):866-75. PubMed ID: 23303584
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunization with trivalent inactivated influenza vaccine in partially immunized toddlers.
    Englund JA; Walter EB; Gbadebo A; Monto AS; Zhu Y; Neuzil KM
    Pediatrics; 2006 Sep; 118(3):e579-85. PubMed ID: 16950949
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction of broad immunity by thermostabilised vaccines incorporated in dissolvable microneedles using novel fabrication methods.
    Vrdoljak A; Allen EA; Ferrara F; Temperton NJ; Crean AM; Moore AC
    J Control Release; 2016 Mar; 225():192-204. PubMed ID: 26774221
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protection of guinea pigs by vaccination with a recombinant swinepox virus co-expressing HA1 genes of swine H1N1 and H3N2 influenza viruses.
    Xu J; Yang D; Huang D; Xu J; Liu S; Lin H; Zhu H; Liu B; Lu C
    Arch Virol; 2013 Mar; 158(3):629-37. PubMed ID: 23135159
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An H1-H3 chimeric influenza virosome confers complete protection against lethal challenge with PR8 (H1N1) and X47 (H3N2) viruses in mice.
    Abdoli A; Soleimanjahi H; Tavassoti Kheiri M; Jamali A; Mazaheri V; Abdollahpour Alitappeh M
    Pathog Dis; 2014 Dec; 72(3):197-207. PubMed ID: 25066138
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity, safety and reactogenicity of a mammalian cell-culture-derived influenza vaccine in healthy children and adolescents three to seventeen years of age.
    Vesikari T; Block SL; Guerra F; Lattanzi M; Holmes S; Izu A; Gaitatzis N; Hilbert AK; Groth N
    Pediatr Infect Dis J; 2012 May; 31(5):494-500. PubMed ID: 22301476
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin.
    Bright RA; Carter DM; Daniluk S; Toapanta FR; Ahmad A; Gavrilov V; Massare M; Pushko P; Mytle N; Rowe T; Smith G; Ross TM
    Vaccine; 2007 May; 25(19):3871-8. PubMed ID: 17337102
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hemagglutinin stem reactive antibody response in individuals immunized with a seasonal influenza trivalent vaccine.
    Zhao X; Qin K; Guo J; Wang D; Li Z; Zhu W; Liu L; Wang D; Shu Y; Zhou J
    Protein Cell; 2015 Jun; 6(6):453-457. PubMed ID: 25940943
    [No Abstract]   [Full Text] [Related]  

  • 15. Evaluation of the immunogenicity and protective effects of a trivalent chimeric norovirus P particle immunogen displaying influenza HA2 from subtypes H1, H3 and B.
    Gong X; Yin H; Shi Y; He X; Yu Y; Guan S; Kuai Z; Haji NM; Haji NM; Kong W; Shan Y
    Emerg Microbes Infect; 2016 May; 5(5):e51. PubMed ID: 27222326
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Insertion-responsive microneedles for rapid intradermal delivery of canine influenza vaccine.
    Choi IJ; Kang A; Ahn MH; Jun H; Baek SK; Park JH; Na W; Choi SO
    J Control Release; 2018 Sep; 286():460-466. PubMed ID: 30102940
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cross-protection against homologous drift variants of influenza A and B after vaccination with split vaccine.
    Heckler R; Baillot A; Engelmann H; Neumeier E; Windorfer A
    Intervirology; 2007; 50(1):58-62. PubMed ID: 17164559
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dose sparing strategy with intradermal influenza vaccination in patients with solid cancer.
    Jo YM; Song JY; Hwang IS; Lee J; Oh SC; Kim JS; Kim SR; Kim WJ; Cheong HJ
    J Med Virol; 2009 Apr; 81(4):722-7. PubMed ID: 19235853
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influenza antigen-sparing by immune stimulation with Gram-positive enhancer matrix (GEM) particles.
    Saluja V; Visser MR; Ter Veer W; van Roosmalen ML; Leenhouts K; Hinrichs WL; Huckriede A; Frijlink HW
    Vaccine; 2010 Nov; 28(50):7963-9. PubMed ID: 20946860
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity of a 2009 pandemic influenza virus A H1N1 vaccine, administered simultaneously with the seasonal influenza vaccine, in children receiving chemotherapy.
    Ottóffy G; Horváth P; Muth L; Sólyom A; Garami M; Kovács G; Nyári T; Molnár D; Pauler G; Jankovics I
    Pediatr Blood Cancer; 2014 Jun; 61(6):1013-6. PubMed ID: 24395342
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.